Moreover, setrusumab, another monoclonal antibody of sclerostin, has exhibited promising treatment potential in a randomized Phase IIb study in adults with OI and in a phase 2/3 ORBIT study involving children and adolescents with OI [40, 41]. Here, SOST is linked to osteogenesis imperfecta.